다른 서비스와 비교했을 때 TTOO 의 PS 비율은 어느 정도인가요?

TTOO is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (17x).

TTOO 의 PS 비율은 US Biotechs 업계의 다른 회사와 어떻게 비교됩니까?

TTOO is good value based on its Price-To-Sales Ratio (2x) compared to the US Biotechs industry average (12.6x).

TTOO 의 PS 비율과 공정 PS 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PS 비율입니다.

Insufficient data to calculate TTOO's Price-To-Sales Fair Ratio for valuation analysis.

미래 현금 흐름을 볼 때 TTOO 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

Insufficient data to calculate TTOO's fair value for valuation analysis.

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

Insufficient data to show price forecast.

T2 Biosystems (Nasdaq:TTOO) - 주가, 뉴스 및 분석

TTOO 주식 개요

체외 진단 회사인 T2 바이오시스템즈는 미국 및 전 세계에서 진단 제품과 제품 후보를 개발 및 판매하는 회사입니다.

회사 소개

TTOO 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

Earnings have grown 1.2% per year over the past 5 years

위험 분석

Shareholders have been substantially diluted in the past year

Negative shareholders equity

Does not have a meaningful market cap ($15M)

Volatile share price over the past 3 months compared to the US market

T2 Biosystems, Inc. 경쟁사

Biora Therapeutics

NasdaqGM:BIOR

US$12.3m

Yubo International Biotech

OTCPK:YBGJ

US$14.4m

OpGen

OTCPK:OPGN

US$15.1m

Longeveron

NasdaqCM:LGVN

US$29.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 T2 Biosystems
과거 주가
현재 주가	US$0.85
52주 최고치	US$8.38
52주 최저치	US$0.82
베타	0.31
11개월 변경	-53.25%
3개월 변경 사항	-79.69%
1년 변경 사항	-84.10%
33년 변화	-99.98%
5년 변화	-99.99%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

주주 수익률

	TTOO	US Biotechs	US 마켓
7D	-19.0%	-0.7%	-1.6%
1Y	-84.1%	19.8%	30.8%

수익률 대 산업: TTOO underperformed the US Biotechs industry which returned 19.8% over the past year.

수익률 대 시장: TTOO underperformed the US Market which returned 30.8% over the past year.

가격 변동성

Is TTOO's price volatile compared to industry and market?
TTOO volatility
TTOO Average Weekly Movement	10.4%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

안정적인 주가: TTOO's share price has been volatile over the past 3 months compared to the US market.

시간에 따른 변동성: TTOO's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of US stocks.

회사 소개

설립	직원	CEO	웹사이트
2006	113	John Sperzel	www.t2biosystems.com

체외 진단 회사인 T2 바이오시스템즈는 미국 및 전 세계에서 진단 제품 및 제품 후보를 개발 및 판매하고 있습니다. 이 회사의 기술을 통해 전혈, 혈장, 혈청, 타액, 가래, 뇌척수액, 소변 등 정제되지 않은 다양한 환자 샘플 유형에서 병원균, 바이오마커 및 기타 이상 징후를 검출할 수 있습니다. 또한 환자 샘플에서 다양한 진단 검사를 실행하는 벤치탑 기기인 T2Dx Instrument와 패혈증과 칸디다증을 유발하는 치명적인 형태의 일반적인 혈류 감염을 검출하는 혈액 직접 분자 진단 검사 패널인 T2Candida 패널을 제공합니다; 혈류 감염의 세균성 병원체를 검출하는 혈액 직접 분자 진단 검사 패널인 T2Bacteria 패널, 카바페넴 내성 유전자를 확인하는 혈액 직접 검사 패널인 T2Resistance 패널, T2Dx 기기에서 실행되어 생물 위협 병원체를 검출하는 혈액 직접 분자 진단 검사 패널인 T2Biothreat 패널이 있습니다.

T2 Biosystems, Inc. 기본 사항 요약

T2 Biosystems 의 수익과 매출은 시가총액과 어떻게 비교하나요?
TTOO 기본 통계
시가총액	US$14.87m
수익(TTM)	-US$48.26m
수익(TTM)	US$7.16m

2.1x

P/S 비율

-0.3x

P/E 비율

TTOO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
TTOO 손익 계산서(TTM)
수익	US$7.16m
수익 비용	US$26.31m
총 이익	-US$19.14m
기타 비용	US$29.12m
수익	-US$48.26m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.76
총 마진	-267.23%
순이익 마진	-673.67%
부채/자본 비율	-199.8%

TTOO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

TTOO 주식 개요

보상

위험 분석

T2 Biosystems, Inc. 경쟁사

NasdaqGM:BIOR

US$12.3m

OTCPK:YBGJ

US$14.4m

OTCPK:OPGN

US$15.1m

NasdaqCM:LGVN

US$29.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

Recent updates

T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M